“…Transition metal complexes have emerged as promising therapeutic tools in photopharmacology due to several unique properties, including a wide range of coordination numbers, oxidation states, and geometries. , Among transition metals, Pt(IV), Ru(II), Rh(III), Ir(III), and Os(II) are very attractive candidates for PDT applications since they tend to absorb in the visible region of the electromagnetic spectrum and exhibit relatively high photostability and long luminescence lifetimes (>100 ns), being an interesting alternative to PSs based on organic fluorophores on clinical use such as porphyrins or chlorins. − In this context, cyclometalated iridium(III) complexes show excellent anticancer activities and a great potential to overcome some of the main drawbacks of conventional platinum-based chemotherapy (i.e., resistance and toxic side effects). , Such metal complexes are likely good candidates for PDT applications as they combine appealing photophysical and photochemical properties within a single compound, including large Stokes’ shifts, high luminescent quantum yield, and high efficient singlet oxygen production upon light irradiation. Photosensitizers based on cyclometalated Ir(III) complexes have been used also as photocatalysts in systems for photocatalytic hydrogen evolution reactions. , However, most reported cyclometalated iridium(III) complexes are quite cytotoxic in the dark and only activatable with short wavelengths of light, which compromises further development of efficient PDT agents.…”